Welcome back to Stockhouse
Member Sign In

Email or Username:

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Enter your email address:
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

Get our best content in your email.

You are already a member! Please enter your password to sign in.
Quote  |  Bullboard  |  News  |  Opinion  |  Level II  |  Charts  |  Profile  |  Financials  |  Options  |  Price History  |  Analysts  |  Earnings  |  Insiders

Nuvo Research Inc T.NRI

Sector: Healthcare | Sub-Sector: Drug Manufacturers - Specialty & Generic
Alternate Symbol(s):  NRIFF| NRIFD

Nuvo Research Inc is a specialty pharmaceutical company with manufacturing operations. The Company operates two distinct business units, the Topical Products and Technology (TPT) Group and the Immunology Group.
Price: $7.12 | Change: +$0.13 | %Change: +1.86%
Volume: 11,352 | Day High/Low: 7.12/6.99 | 52 Week High/Low: 10.36/3.81
View modes: 
0 stars

Going Forward

Its apparent that Nuvo is already very profitable in its manufacturing and commercial drug sales. For P2, net margins are already at $30 per bottle. Current production volumes are low compared more
3 stars

Lots of Expansion Potential for P2 plant.

The Varennes plant has 26,000 sq ft of space. About half of this is set aside for drug manufacturing. What is its ultimate capacity ? This plant manufactured 110,000 btls of P2 in the first 6 more
2 stars

Cost To Produce P2

I use the cost to produce a 355ml of Coke which I googled. The bottle/can and the plastic wrapper  cost to about 6 cents.  The Coke syrup and carbonation adds about 10 cents to the more
2 stars

RE:RE:RE:RE:RE:Zack's Latest Report

No need to talk to JL. All Zeng had to do was look at H1  2015 operating financials.  Nuvo had $14.3 million in total expenses in H1. Remove Newco costs of  $6.3 m in R&D and $ more
2.5 stars

RE:RE:RE:RE:RE:Zack's Latest Report

How can that be ? C99 states that Jason also got his facts from JL. Remarkably different conclusions from the same source, wouldnt you say? If in fact JL was the source. Which I doubt. BTW, more
3.5 stars

RE:RE:RE:RE:Zack's Latest Report

I believe Zeng did no more than state exactly what Nuvo management had to say about the proposed split. No more, no less. I'd like to think he has optimism for Nuvo, as many of us do, but what more
3 stars

RE:RE:RE:Zack's Latest Report

What is interesting about this updated report is, as c99 pointed out, a quite different forecast for Nuvo. The analyst is no longer Napodamo Its a new chap Zeng. He has a quite different view on more
5 stars

RE:RE:Zack's Latest Report

3 stars

RE:Zack's Latest Report

I refer only to 2016. Zacks increase in P2 sales in 2017 and beyond seem to be quite arbitrary. They increase by $4 million per year. I fail to understand your fixation with management more
5 stars

Zack's Latest Report

Zack's Sept Report Not much new information except the assertion by  Zack's "We estimate the specialty pharma company will become profitable immediately after the separation". more
0 stars

RE:Is $375 Million in P2 sales Possible in 2016

The P2 sales revenues in 2016 are not all US based. While not specific as to the split some are likely going to come from South America and some from the EU; Zack's says that is where more
5 stars

Is $375 Million in P2 sales Possible in 2016

If Zacks report is accepted and  4 % product margin, $15 million in P2 product sales by Nuvo in 2016 would be  $375 million US in Sales by Horizon. Total P2 sales by Horizon in the more
5 stars


What the buyer at TD knew in early August is now seeping into general knowledge. With no PR program it takes several days for good news to become known. The spin-out is very good news which more
1 star


I know you are a long timer like myself(12 years). I sold a couple of years back just before the reverse split at 7 to 5 cents. With $6.50 rounded out you are still looking at about 10 cents pre rs. more
1 star

Insiders buying Insiders have been heavily buying shares in three stocks in September. They all look good for a buy on Monday.  rate and reply
5 stars


Nice... The technicals are looking great with the moving averages crossing sending a strong bullish signal; gap fill from $6.40 to $8.59 is my next upside target. Level II selling is minimal more
0 stars


There you go Ronz.  rate and reply
5 stars

Spin Out

Its worthwhile to review the drugs which will go with the Wf10 spin-out. There are altogether about 13 drugs in various stages of development. While none other than WF10 and perhaps Ibufoam seem more
0 stars

RE:Drug Market in Europe

It puts the obvious option in clear perspective. JL has always said that they would seek a major distributor in Europe and would build royaties into the price sold to that distributor. This more
0 stars

RE:RE:RE:RE:RE:Zacks August Report

2 nitty gritty posts bigz, thanku  rate and reply